Stephanie Davis
Stock Analyst at Barclays
(1.15)
# 3,466
Out of 4,784 analysts
103
Total ratings
33.33%
Success rate
-15.34%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAY Waystar Holding | Maintains: Overweight | $42 → $50 | $37.83 | +32.17% | 2 | Feb 19, 2025 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $168 → $175 | $167.33 | +4.58% | 4 | Jan 31, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $8.64 | -42.13% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $58.51 | +28.18% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $6.70 | +4.48% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $4.50 | +33.33% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $9.60 | +97.92% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $275.21 | +5.37% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $19.14 | +25.39% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $136.44 | -2.52% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $35.01 | +65.67% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.63 | +14.07% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $0.50 | +50.12% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5.5 → $5 | $6.99 | -28.47% | 10 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $230.02 | +8.25% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $26.00 | +11.54% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.09 | +320.27% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.90 | +55.25% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $234.21 | -0.52% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $4.55 | +273.63% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $86.96 | -12.60% | 5 | Jun 7, 2022 |
Waystar Holding
Feb 19, 2025
Maintains: Overweight
Price Target: $42 → $50
Current: $37.83
Upside: +32.17%
Quest Diagnostics
Jan 31, 2025
Maintains: Equal-Weight
Price Target: $168 → $175
Current: $167.33
Upside: +4.58%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $8.64
Upside: -42.13%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $58.51
Upside: +28.18%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $6.70
Upside: +4.48%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $4.50
Upside: +33.33%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $9.60
Upside: +97.92%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $275.21
Upside: +5.37%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $19.14
Upside: +25.39%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $136.44
Upside: -2.52%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $35.01
Upside: +65.67%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.63
Upside: +14.07%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $0.50
Upside: +50.12%
Oct 9, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $5
Current: $6.99
Upside: -28.47%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $230.02
Upside: +8.25%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $26.00
Upside: +11.54%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.09
Upside: +320.27%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.90
Upside: +55.25%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $234.21
Upside: -0.52%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $4.55
Upside: +273.63%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $86.96
Upside: -12.60%